premargin

Element List	Explanation
Introduction	Middle East Pharmaceutical Industries Co. announces the execution of a strategic commercialization agreement with Bio-Thera Solutions. Pursuant to the agreement, Avalon Pharma has been granted exclusive rights to register and commercialize Pembrolizumab, a Proposed Keytruda® Biosimilar, across the Kingdom of Saudi Arabia and Middle East and North Africa (MENA) markets.
Date of Announcement of the Award	2026-02-03 Corresponding to 1447-08-15
Contract Subject Matter	Exclusive License to register and commercialize Pembrolizumab in Saudi Arabia and MENA markets with the provision to make the technology transfer localize the manufacturing of the product in the future.
The Entity with Which the Contract was Signed	Bio-Thera Solutions Inc. A global biopharmaceutical company specializing in innovative biologics and biosimilars
Date of Signing the Contract	2026-02-03 Corresponding to 1447-08-15
Contract Value	The value of the contract represents above 5% of the Company’s revenues.
Contract Details	This Contract grants Middle East Pharmaceutical Industries Co. the exclusive license rights to register and commercialize “Pembrolizumab”, a Proposed Keytruda® Biosimilar, across the Kingdom of Saudi Arabia and Middle East and North Africa (MENA) markets with additional rights to localize the manufacturing of the product in the future.
Contract Duration	15 Years eligible for renewal
Financial Impact and the Relevant Period	2030 onwards, estimating the incremental revenue of no less than 500 Mn SAR during the contract period
Related Parties	There are no related parties involved in this transaction.
Additional Information	Partnership strengthens patient access to oncology therapies and aligns with Saudi Arabia's Vision 2030 objectives
Attached Documents	Attached Documents

Middle East Pharmaceutical Industries Co. Announces Contract Sign Off with Bio-Thera Solutions Inc. A global biopharmaceutical company specializing in innovative biologics and biosimilars